Fluidigm Corporation (NASDAQ: FLDM) and Medical Transcription Billing, Corp. (NASDAQ:MTBC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk and valuation.
Volatility & Risk
Fluidigm Corporation has a beta of 3.45, suggesting that its stock price is 245% more volatile than the S&P 500. Comparatively, Medical Transcription Billing, Corp. has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500.
91.4% of Fluidigm Corporation shares are held by institutional investors. Comparatively, 9.6% of Medical Transcription Billing, Corp. shares are held by institutional investors. 4.7% of Fluidigm Corporation shares are held by company insiders. Comparatively, 53.5% of Medical Transcription Billing, Corp. shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Fluidigm Corporation and Medical Transcription Billing, Corp.’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Fluidigm Corporation||$96.72 million||1.11||-$62.62 million||($2.46)||-1.48|
|Medical Transcription Billing, Corp.||$30.18 million||0.55||-$2.56 million||($1.08)||-1.33|
Medical Transcription Billing, Corp. has higher revenue, but lower earnings than Fluidigm Corporation. Fluidigm Corporation is trading at a lower price-to-earnings ratio than Medical Transcription Billing, Corp., indicating that it is currently the more affordable of the two stocks.
This is a summary of recent ratings and recommmendations for Fluidigm Corporation and Medical Transcription Billing, Corp., as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Medical Transcription Billing, Corp.||0||0||1||0||3.00|
Fluidigm Corporation presently has a consensus price target of $9.00, indicating a potential upside of 147.25%. Medical Transcription Billing, Corp. has a consensus price target of $2.25, indicating a potential upside of 56.25%. Given Fluidigm Corporation’s higher probable upside, research analysts clearly believe Fluidigm Corporation is more favorable than Medical Transcription Billing, Corp..
This table compares Fluidigm Corporation and Medical Transcription Billing, Corp.’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Medical Transcription Billing, Corp.||-32.88%||-59.52%||-19.17%|
Fluidigm Corporation beats Medical Transcription Billing, Corp. on 6 of the 11 factors compared between the two stocks.
Fluidigm Corporation Company Profile
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. Its products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents. Its preparatory instruments include C1 Single-Cell Auto Prep System, Access Array System, Juno System and IFCs, and Callisto System and IFC. Its analytical instruments include Biomark HD System, EP1 System and Helios/CyTOF 2 System. Its assays and reagents include Delta Gene and SNP Type Assays, and Access Array Target-Specific Primers and Targeted Sequencing Prep Primers.
Medical Transcription Billing, Corp. Company Profile
Medical Transcription Billing, Corp. is a healthcare information technology company that provides an integrated suite of Web-based solutions, together with related business services, to healthcare providers practicing in ambulatory care settings. The Company’s offering, PracticePro, allows healthcare practices with the core software and business services on Software-as-a-Service (SaaS) platform. PracticePro includes practice management software and related tools, which facilitate the day-to-day operation of a medical practice; electronic health records (EHR), which allow its customers to qualify for government incentives; revenue cycle management (RCM) services, which include medical billing, analytics and related services, and mobile Health (mHealth) solutions, including smartphone applications that assist patients and healthcare providers in the provision of healthcare services. The Company offers a clearinghouse service, which allows clients to track claim status.
What are top analysts saying about Fluidigm Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Fluidigm Corporation and related companies.